Investments – Equity Securities	9 Months Ended
Sep. 30, 2025
Investments, All Other Investments [Abstract]
Investments – Equity Securities	9. Investments – Equity Securities On August 5, 2025, the Company entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. (“Defeye”), a privately held Delaware corporation, under which the Company received 7,198,630 shares of Defeye’s Series Seed-2 Preferred Stock in exchange for the issuance of $2,890 of product purchase credits pursuant to a related supply and distribution agreement. The investment in Defeye represents an equity investment without significant influence and is accounted for in accordance with ASC 321, Investments—Equity Securities. Because Defeye’s shares are not publicly traded and their fair value is not readily determinable, the Company elected to apply the measurement alternative under ASC 321. Under this approach, the investment is measured at cost, less any impairment, and adjusted for observable price changes in orderly transactions for the same or similar securities of Defeye. As of August 5, 2025, the Defeye Preferred Stock carrying value of $2,890 was recorded as Investments – Equity Securities in the condensed consolidated balance sheets. The fair value of the consideration transferred, represented by the product purchase credits, was recorded as Deferred Revenue (Contract Liability) on the condensed consolidated balance sheet in accordance with ASC 606, Revenue from Contracts with Customers, as the Company has an obligation to deliver product to Defeye in future periods. Revenue will be recognized as product is delivered under the supply agreement. As of September 30, 2025, no impairment indicators or observable price changes were identified related to the Defeye investment.

Investments – Equity Securities

9 Months Ended

Sep. 30, 2025

Investments, All Other Investments [Abstract]

9. Investments – Equity Securities

On August 5, 2025, the Company entered into a Series Seed Preferred Stock Purchase Agreement with Defeye, Inc. (“Defeye”), a privately held Delaware corporation, under which the Company received 7,198,630 shares of Defeye’s Series Seed-2 Preferred Stock in exchange for the issuance of $2,890 of product purchase credits pursuant to a related supply and distribution agreement.

The investment in Defeye represents an equity investment without significant influence and is accounted for in accordance with ASC 321, Investments—Equity Securities. Because Defeye’s shares are not publicly traded and their fair value is not readily determinable, the Company elected to apply the measurement alternative under ASC 321. Under this approach, the investment is measured at cost, less any impairment, and adjusted for observable price changes in orderly transactions for the same or similar securities of Defeye. As of August 5, 2025, the Defeye Preferred Stock carrying value of $2,890 was recorded as Investments – Equity Securities in the condensed consolidated balance sheets.

The fair value of the consideration transferred, represented by the product purchase credits, was recorded as Deferred Revenue (Contract Liability) on the condensed consolidated balance sheet in accordance with ASC 606, Revenue from Contracts with Customers, as the Company has an obligation to deliver product to Defeye in future periods. Revenue will be recognized as product is delivered under the supply agreement.

As of September 30, 2025, no impairment indicators or observable price changes were identified related to the Defeye investment.